Adult trials (Ages 18 and older)

Interventional trials

All Mutation Types (KIT, PDGFRA D842V, Wild)

2nd Line Only

IRB #19262
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)

3rd or 4th Line

IRB #20580
Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies

KIT and PDGFRA (D842V) Mutations

At least 1 prior therapy

IRB #17155
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

PDGFRA D842V Only

2nd or 3rd Line

IRB #31229
Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects with Advanced Gastrointestinal Stromal Tumor

SDH-Mutant/deficient GIST

IRB #21884
An Open-Label, Phase 2 Efficacy Study of Temozolomide in Advanced SDH Mutant/Deficient GIST

Adult and Pediatrics

Interventional trials

Cross-Disease Trials:

IRB# 19992
EAY131 (MATCH)

IRB# 18084
S1609 (DART)

http://www.ohsu.edu/research/rda/so/knight.php